Physicians

Donald E. Cutlip MD

Executive Director, Clinical Investigations, HCRI
Faculty, Beth Israel Deaconess Medical Center
Interventional Cardiology, Stent Thrombosis, Diabetes

Biography

Donald Cutlip MD is an Interventional Cardiologist and serves as Executive Director of Clinical Investigation at HCRI. In this role he works closely with the groups responsible for management of the Clinical Event Committee and Data and Safety Monitoring Board activities.

He also works with industry sponsors in early clinical trial design and planning activities, and collaborates with other Harvard investigators in developing initial clinical trial designs and functional academic and industry alliances. He maintains a full time appointment on the Interventional Cardiology staff at Beth Israel Deaconess Medical Center, where he is Director of Interventional Cardiology Research and is Associate Professor of Medicine at Harvard Medical School.

He has co-authored several original publications in the field of Interventional Cardiology and related clinical trials.

Phone

617.632.1515

Address

930 Commonwealth Avenue
Boston, MA 02215

Significant Publications

Detailed intravascular ultrasound analysis of Zotarolimus-eluting phosphorylcholine-coated cobalt-chromium alloy stent in de novo coronary lesions (results from the ENDEAVOR II trial). Am J Cardiol. 2007 Sep 1;100(5):818-23.

Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation. 2007 Jun 5;115(22):2842-7.

Risk of target lesion revascularization after coronary stenting in patients with and without chronic kidney disease. Nephrol Dial Transplant. 2007 Sep;22(9):2578-85.

Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007 May 1;115(17):2344-51.

Drug eluting stents for ST-elevation myocardial infarction: risk and benefit J Thromb Thrombolysis. 2007 Dec;24(3):293-9.